Inflammation and Cardiovascular Disease: The Future

Despite considerable advances in reducing the global burden of atherosclerotic cardiovascular disease by targeting conventional risk factors, significant residual risk remains, with low-grade inflammation being one of the strongest risk modifiers. Inflammatory processes within the arterial wall or s...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Natalie Arnold, Katharina Lechner, Christoph Waldeyer, Michael D Shapiro, Wolfgang Koenig
Formato:	article
Lenguaje:	EN
Publicado:	Radcliffe Medical Media 2021
Materias:	Diseases of the circulatory (Cardiovascular) system RC666-701
Acceso en línea:	https://doaj.org/article/c298196d799e49f5b196ebfb168e1c33
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c298196d799e49f5b196ebfb168e1c33
record_format	dspace
spelling	oai:doaj.org-article:c298196d799e49f5b196ebfb168e1c332021-12-04T16:04:29ZInflammation and Cardiovascular Disease: The Future10.15420/ecr.2020.501758-37641758-3756https://doaj.org/article/c298196d799e49f5b196ebfb168e1c332021-05-01T00:00:00Zhttps://www.ecrjournal.com/articleindex/ecr.2020.50https://doaj.org/toc/1758-3756https://doaj.org/toc/1758-3764Despite considerable advances in reducing the global burden of atherosclerotic cardiovascular disease by targeting conventional risk factors, significant residual risk remains, with low-grade inflammation being one of the strongest risk modifiers. Inflammatory processes within the arterial wall or systemic circulation, which are driven in a large part by modified lipoproteins but subsequently trigger a hypercoagulable state, are a hallmark of atherosclerotic cardiovascular disease and, in particular, its clinical complications. Extending conventional guideline-based clinical risk stratification algorithms by adding biomarkers of inflammation may refine phenotypic screening, improve risk stratification and guide treatment eligibility in cardiovascular disease prevention. The integration of interventions aimed at lowering the inflammatory burden, alone or in combination with aggressive lipid-modifying or even antithrombotic agents, for those at high cardiovascular risk may hold the potential to reduce the still substantial burden of cardiometabolic disease. This review provides perspectives on future clinical research in atherosclerosis addressing the tight interplay between inflammation, lipid metabolism and thrombosis, and its translation into clinical practice.Natalie ArnoldKatharina LechnerChristoph WaldeyerMichael D ShapiroWolfgang KoenigRadcliffe Medical MediaarticleDiseases of the circulatory (Cardiovascular) systemRC666-701ENEuropean Cardiology Review , Vol 16, Iss , Pp - (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the circulatory (Cardiovascular) system RC666-701
spellingShingle	Diseases of the circulatory (Cardiovascular) system RC666-701 Natalie Arnold Katharina Lechner Christoph Waldeyer Michael D Shapiro Wolfgang Koenig Inflammation and Cardiovascular Disease: The Future
description	Despite considerable advances in reducing the global burden of atherosclerotic cardiovascular disease by targeting conventional risk factors, significant residual risk remains, with low-grade inflammation being one of the strongest risk modifiers. Inflammatory processes within the arterial wall or systemic circulation, which are driven in a large part by modified lipoproteins but subsequently trigger a hypercoagulable state, are a hallmark of atherosclerotic cardiovascular disease and, in particular, its clinical complications. Extending conventional guideline-based clinical risk stratification algorithms by adding biomarkers of inflammation may refine phenotypic screening, improve risk stratification and guide treatment eligibility in cardiovascular disease prevention. The integration of interventions aimed at lowering the inflammatory burden, alone or in combination with aggressive lipid-modifying or even antithrombotic agents, for those at high cardiovascular risk may hold the potential to reduce the still substantial burden of cardiometabolic disease. This review provides perspectives on future clinical research in atherosclerosis addressing the tight interplay between inflammation, lipid metabolism and thrombosis, and its translation into clinical practice.
format	article
author	Natalie Arnold Katharina Lechner Christoph Waldeyer Michael D Shapiro Wolfgang Koenig
author_facet	Natalie Arnold Katharina Lechner Christoph Waldeyer Michael D Shapiro Wolfgang Koenig
author_sort	Natalie Arnold
title	Inflammation and Cardiovascular Disease: The Future
title_short	Inflammation and Cardiovascular Disease: The Future
title_full	Inflammation and Cardiovascular Disease: The Future
title_fullStr	Inflammation and Cardiovascular Disease: The Future
title_full_unstemmed	Inflammation and Cardiovascular Disease: The Future
title_sort	inflammation and cardiovascular disease: the future
publisher	Radcliffe Medical Media
publishDate	2021
url	https://doaj.org/article/c298196d799e49f5b196ebfb168e1c33
work_keys_str_mv	AT nataliearnold inflammationandcardiovasculardiseasethefuture AT katharinalechner inflammationandcardiovasculardiseasethefuture AT christophwaldeyer inflammationandcardiovasculardiseasethefuture AT michaeldshapiro inflammationandcardiovasculardiseasethefuture AT wolfgangkoenig inflammationandcardiovasculardiseasethefuture
_version_	1718372699316682752

Inflammation and Cardiovascular Disease: The Future

Ejemplares similares